Literature DB >> 9862779

Dynorphin A1-13 causes elevation of serum levels of prolactin through an opioid receptor mechanism in humans: gender differences and implications for modulation of dopaminergic tone in the treatment of addictions.

M J Kreek1, J Schluger, L Borg, M Gunduz, A Ho.   

Abstract

Dynorphin peptides act preferentially at kappa- as well as mu- and delta-opioid receptors. This study was conducted to determine whether dynorphin peptides act to lower dopaminergic tone in the tuberoinfundibular system, resulting in elevated serum prolactin levels and, if so, whether such an effect is mediated by the opioid receptors. Dose-related increases in serum prolactin levels were observed after dynorphin A1-13 was administered i.v. in doses of 120 and 500 micrograms/kg to healthy human volunteers with no history of drug or alcohol abuse. Studies were then conducted to determine whether this effect is opioid receptor mediated and, if so, whether at kappa- or mu types. Pretreatment with the opioid antagonist nalmefene (30 mg i.v.), which has high affinity at both mu- and kappa-opioid receptors, caused a greater attenuation in dynorphin A1-13-stimulated increases in serum prolactin levels than pretreatment with similarly high doses of naloxone, an antagonist with lower affinity for both mu- and kappa-opioid receptors. These results suggest dynorphin A1-13 lowers tuberoinfundibular dopaminergic tone through action at kappa- and possibly mu-opioid receptors. Female subjects were significantly more responsive to the prolactin effects of dynorphin than were male subjects. Dynorphin gene expression, dynorphin peptides, and kappa-opioid receptor gene expression and binding have been shown to be altered in response to cocaine administration. Also, both dynorphin peptides and synthetic kappa-opioid agonists have been shown to lower dopamine levels in the nucleus accumbens and to attenuate cocaine-induced surges in dopamine levels. Thus, a dynorphin-like compound capable of reaching critical mesolimbic-mesocortical and nigrostriatal dopaminergic systems may be effective in the management of cocaine addiction.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9862779

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  24 in total

1.  The κ-opioid receptor gene as a predictor of response in a cocaine vaccine clinical trial.

Authors:  David A Nielsen; Sara C Hamon; Thomas R Kosten
Journal:  Psychiatr Genet       Date:  2013-12       Impact factor: 2.458

Review 2.  Role of a functional human gene polymorphism in stress responsivity and addictions.

Authors:  M J Kreek
Journal:  Clin Pharmacol Ther       Date:  2008-03-05       Impact factor: 6.875

3.  A single injection of the kappa opioid antagonist norbinaltorphimine increases ethanol consumption in rats.

Authors:  Jennifer M Mitchell; Marisa T Liang; Howard L Fields
Journal:  Psychopharmacology (Berl)       Date:  2005-10-19       Impact factor: 4.530

4.  Preclinical evaluation of the kappa-opioid receptor antagonist CERC-501 as a candidate therapeutic for alcohol use disorders.

Authors:  E Domi; E Barbier; E Augier; G Augier; D Gehlert; R Barchiesi; A Thorsell; L Holm; M Heilig
Journal:  Neuropsychopharmacology       Date:  2018-02-05       Impact factor: 7.853

5.  Potentially functional polymorphism in the promoter region of prodynorphin gene may be associated with protection against cocaine dependence or abuse.

Authors:  Andrew C H Chen; K Steven LaForge; Ann Ho; Pauline F McHugh; Scott Kellogg; Kathy Bell; Rosemary P Schluger; Suzanne M Leal; Mary Jeanne Kreek
Journal:  Am J Med Genet       Date:  2002-05-08

6.  The effects of herkinorin, the first mu-selective ligand from a salvinorin A-derived scaffold, in a neuroendocrine biomarker assay in nonhuman primates.

Authors:  Eduardo R Butelman; Szymon Rus; Denise S Simpson; Angela Wolf; Thomas E Prisinzano; Mary Jeanne Kreek
Journal:  J Pharmacol Exp Ther       Date:  2008-07-01       Impact factor: 4.030

7.  Effects of nalbuphine on anterior pituitary and adrenal hormones and subjective responses in male cocaine abusers.

Authors:  Nathalie V Goletiani; Jack H Mendelson; Michelle B Sholar; Arthur J Siegel; Alicja Skupny; Nancy K Mello
Journal:  Pharmacol Biochem Behav       Date:  2007-02-20       Impact factor: 3.533

Review 8.  Peptide kappa opioid receptor ligands: potential for drug development.

Authors:  Jane V Aldrich; Jay P McLaughlin
Journal:  AAPS J       Date:  2009-05-09       Impact factor: 4.009

9.  Ovarian steroids alter mu opioid receptor trafficking in hippocampal parvalbumin GABAergic interneurons.

Authors:  Annelyn Torres-Reveron; Tanya J Williams; Jeanette D Chapleau; Elizabeth M Waters; Bruce S McEwen; Carrie T Drake; Teresa A Milner
Journal:  Exp Neurol       Date:  2009-06-06       Impact factor: 5.330

10.  Sex differences in U50,488H-induced phosphorylation of p44/42 mitogen-activated protein kinase in the guinea pig brain.

Authors:  K Rasakham; K L McGillivray; L-Y Liu-Chen
Journal:  Neuroscience       Date:  2012-07-31       Impact factor: 3.590

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.